Progyny, Inc. Announces Third Quarter 2026 Results
Progyny, Inc. (PGNY) filed an SEC Form 8-K — Results of Operations and Financial Condition. Progyny, Inc. Announces Third Quarter 2026 Results Reports Record Third Quarter Results for Revenue, Gross Profit, Adjusted EBITDA and Net Income Selling Season Yields Record 1.3 Million New Covered Lives with Another Year of Near 100% Retention Raises Midpoint of Full Year Guida
How this was made
The 30-second read
Why it matters
The earnings beat and raised guidance provide fresh material for traders to consider positioning ahead of the full‑year results.
Market read
The earnings release adds new quantitative data and a guidance raise, making it a primary catalyst for PGNY and related health‑benefits stocks.
What to watch
The company’s cash burn from share repurchases and a $200M undrawn credit facility may limit upside.
Background
Progyny is a Nasdaq‑listed provider of fertility and family‑building benefits. The filing is an SEC Form 8‑K reporting its Q3 2026 results.
Ticker impact
Progyny reported Q3 2026 revenue of $341.3M, 8.9% growth, and raised the midpoint of its full-year guidance.
likely upward pressure as investors price in stronger top‑line growth and higher guidance.
The company posted higher revenue, gross profit and net income versus the prior year and explicitly raised its guidance midpoint, which typically supports a price rally.
Market effects
Strong results may boost sentiment in the fertility‑benefits and health‑services sector.
U.S. investors focused on health‑tech may see a modest rally in related stocks.
Limited; impact confined to U.S. listed health‑benefits providers.
Counterpoint
If the market has already priced in the guidance raise, the stock could face a short‑term pull‑back.
Key entities
- companyProgyny, Inc.
NASDAQ‑listed provider of women's health and family‑building solutions.
